3 ms·
The article doesn’t explain why you can’t throw a lot of money at licensing out and expanding the production of lipid nanoparticle machines that it identifies a
by ummonk 6y ago
The article doesn’t explain why you can’t throw a lot of money at licensing out and expanding the production of lipid nanoparticle machines that it identifies as a bottleneck.
- dllthomas 6y agoI mostly agree. He touches on it, but it's based on assumption and entirely superficial: "That doesn’t mean that you can’t build more of the machines, but I would assume that Pfizer, BioNTech, Moderna (and CureVac as well) have largely taken up the production capacity for that sort of expansion as well." The obvious question, then, is whether that production capacity could be increased, and whether we have a problem of throughput (which added resources might parallelize) or latency (and we will have all the devices we want, N months from now).